awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36498695-4185C08C-EF28-4BCD-AFD9-21E1B895C944
Q36498695-4185C08C-EF28-4BCD-AFD9-21E1B895C944
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36498695-4185C08C-EF28-4BCD-AFD9-21E1B895C944
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
P2860
Q36498695-4185C08C-EF28-4BCD-AFD9-21E1B895C944
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36498695-4185C08C-EF28-4BCD-AFD9-21E1B895C944
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
95b0fe82907eb6d30d9b2b5e6a1eef88e2ca040e
P2860
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.